Age-appropriate solid oral formulations for pediatric applications with a focus on multiparticulates and minitablets:

David Harris1, Esmerald Hermans2, Sandra Klein3

  • 1Merck & Co, Inc, 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA.

Insights

Pediatric drug development shows promise for multiparticulates and minitablets, especially in stick-packs or capsules. Key challenges include formulation acceptance, food compatibility, and improved dosing devices for pediatric patients.

Area of Science:

  • Pharmaceutical Science
  • Pediatric Drug Delivery

Background:

  • The European Paediatric Formulation Initiative (EuPFI) workshop addressed pediatric formulation development.
  • Multiparticulates and minitablets are explored as age-appropriate dosage forms for children.

Purpose of the Study:

  • To discuss the development of multiparticulates and minitablets for pediatric formulations.
  • To identify challenges and opportunities in pediatric drug product design.

Main Methods:

  • Workshop discussions at the 11th Annual Conference of EuPFI.
  • Focus on formulation platform selection, packaging, and administration methods.

Main Results:

  • Significant interest in stick-packs and capsules for younger children.
  • Adult-sized tablets/capsules deemed suitable for adolescents.
  • Identified challenges: acceptability, soft food compatibility, co-administration, and dosing devices.

Conclusions:

  • Multiparticulates and minitablets are viable pediatric formulation options.
  • Further research is needed to address technical challenges in administration and packaging.
  • Development of specialized dosing devices is crucial for pediatric drug delivery.

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
99
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
115
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
161
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
159
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
141
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
182